Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - Jama, 2022 - jamanetwork.com
Importance Among patients younger than 21 years of age, the optimal duration of
anticoagulant therapy for venous thromboembolism is unknown. Objective To test the …
anticoagulant therapy for venous thromboembolism is unknown. Objective To test the …
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - 2022 - pubmed.ncbi.nlm.nih.gov
Importance Among patients younger than 21 years of age, the optimal duration of
anticoagulant therapy for venous thromboembolism is unknown. Objective To test the …
anticoagulant therapy for venous thromboembolism is unknown. Objective To test the …
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age with Provoked Venous …
NA Goldenberg, F Hamblin, JF Casella, JM Kittelson… - JAMA, 2022 - elibrary.ru
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding
Events in Patients Younger Than 21 Years of Age with Provoked Venous Thromboembolism …
Events in Patients Younger Than 21 Years of Age with Provoked Venous Thromboembolism …
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - JAMA, 2022 - europepmc.org
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in
Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The …
Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The …
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age with Provoked Venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - JAMA, 2022 - pure.johnshopkins.edu
Importance: Among patients younger than 21 years of age, the optimal duration of
anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the …
anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the …
[HTML][HTML] Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - JAMA, 2022 - ncbi.nlm.nih.gov
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding
Events in Patients Younger Than 21 Years of Age With Provoked Venous …
Events in Patients Younger Than 21 Years of Age With Provoked Venous …
[PDF][PDF] Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - JAMA, 2022 - ictr.johnshopkins.edu
OBJECTIVE To test the hypothesis that a 6-week duration of anticoagulant therapy for
provoked venous thromboembolism is noninferior to a conventional 3-month therapy …
provoked venous thromboembolism is noninferior to a conventional 3-month therapy …
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous …
NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca… - JAMA, 2022 - europepmc.org
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in
Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The …
Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The …